Access the CEO Connect segment hereLA JOLLA, CA, March 18, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a ...

在一个波动剧烈的交易日中，GRI股价跌至52周新低，触及5.12美元。根据 InvestingPro 分析，该股票在当前价位显示被低估，技术指标表明出现超卖状态。公司保持着3.43的健康流动比率，显示其具有强劲的短期流动性。这次显著下跌反映了投资者普遍持谨慎态度，市场参与者正在经济不确定性的背景下重新评估其持仓。与Vallon ...

GRI Bio, Inc., a biotechnology firm focused on developing treatments for inflammatory, fibrotic, and autoimmune diseases, announced that CEO Marc Hertz took part in a Virtual Investor CEO Connect ...

As of December 31, 2024, the Company had cash and cash equivalents of approximately $5.0 million. Based on the Company’s current operating ...

LA JOLLA, CA, March 18, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T ...

LA JOLLA, CA, March 11, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T ...

LA JOLLA, CA, March 18, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) ("GRI Bio” or the "Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T ("NKT”) cell ...

About GRI Bio, Inc. GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio’s therapies are ...

GRI Bio, Inc. announced its participation in the Virtual Investor "Top 5 for '25" On-Demand Conference, where CEO Marc Hertz, Ph.D., presented compelling reasons for investors to pay attention to ...

LA JOLLA, CA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell ...